JP2003532636A5 - - Google Patents

Download PDF

Info

Publication number
JP2003532636A5
JP2003532636A5 JP2001562555A JP2001562555A JP2003532636A5 JP 2003532636 A5 JP2003532636 A5 JP 2003532636A5 JP 2001562555 A JP2001562555 A JP 2001562555A JP 2001562555 A JP2001562555 A JP 2001562555A JP 2003532636 A5 JP2003532636 A5 JP 2003532636A5
Authority
JP
Japan
Prior art keywords
ion exchange
reverse phase
phase hplc
exchange chromatography
method described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001562555A
Other languages
English (en)
Japanese (ja)
Other versions
JP4959898B2 (ja
JP2003532636A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2001/000666 external-priority patent/WO2001062774A2/en
Publication of JP2003532636A publication Critical patent/JP2003532636A/ja
Publication of JP2003532636A5 publication Critical patent/JP2003532636A5/ja
Application granted granted Critical
Publication of JP4959898B2 publication Critical patent/JP4959898B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2001562555A 2000-02-22 2001-01-22 Lhの精製 Expired - Lifetime JP4959898B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00103692.0 2000-02-22
EP00103692 2000-02-22
PCT/EP2001/000666 WO2001062774A2 (en) 2000-02-22 2001-01-22 Purified lh

Publications (3)

Publication Number Publication Date
JP2003532636A JP2003532636A (ja) 2003-11-05
JP2003532636A5 true JP2003532636A5 (cg-RX-API-DMAC7.html) 2008-03-21
JP4959898B2 JP4959898B2 (ja) 2012-06-27

Family

ID=8167926

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001562555A Expired - Lifetime JP4959898B2 (ja) 2000-02-22 2001-01-22 Lhの精製

Country Status (30)

Country Link
US (2) US7053054B2 (cg-RX-API-DMAC7.html)
EP (2) EP1261622B1 (cg-RX-API-DMAC7.html)
JP (1) JP4959898B2 (cg-RX-API-DMAC7.html)
KR (1) KR100808149B1 (cg-RX-API-DMAC7.html)
CN (1) CN100480258C (cg-RX-API-DMAC7.html)
AT (1) ATE356138T1 (cg-RX-API-DMAC7.html)
AU (1) AU780377B2 (cg-RX-API-DMAC7.html)
BG (1) BG65761B1 (cg-RX-API-DMAC7.html)
BR (2) BR122012018280B8 (cg-RX-API-DMAC7.html)
CA (1) CA2399100C (cg-RX-API-DMAC7.html)
CY (1) CY1108056T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ303274B6 (cg-RX-API-DMAC7.html)
DE (1) DE60127100T2 (cg-RX-API-DMAC7.html)
DK (1) DK1261622T3 (cg-RX-API-DMAC7.html)
EA (1) EA004385B1 (cg-RX-API-DMAC7.html)
EE (1) EE04932B1 (cg-RX-API-DMAC7.html)
ES (1) ES2278722T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20020651B1 (cg-RX-API-DMAC7.html)
HU (1) HU227007B1 (cg-RX-API-DMAC7.html)
IL (2) IL151309A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02007867A (cg-RX-API-DMAC7.html)
NO (1) NO328693B1 (cg-RX-API-DMAC7.html)
PL (1) PL207728B1 (cg-RX-API-DMAC7.html)
PT (1) PT1261622E (cg-RX-API-DMAC7.html)
RS (1) RS50416B (cg-RX-API-DMAC7.html)
SI (1) SI1261622T1 (cg-RX-API-DMAC7.html)
SK (1) SK287041B6 (cg-RX-API-DMAC7.html)
UA (2) UA92145C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001062774A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200206108B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020651B1 (en) * 2000-02-22 2011-01-31 Laboratoires Serono Sa Purified lh
DE10235168A1 (de) * 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
DE602004030546D1 (de) * 2003-03-04 2011-01-27 Aspenbio Pharma Inc LH zur Verwendung der Erhaltung einer oder mehreren Schwangerschaften durch Induktion der Bildung des sekundären Gelbkörpers.
CN1283792C (zh) * 2003-11-14 2006-11-08 余伟明 生物大分子组分相分离法
ATE446314T1 (de) * 2003-12-22 2009-11-15 Ares Trading Sa Methode zur reinigung von fsh
ATE469912T1 (de) * 2004-10-04 2010-06-15 Novetide Ltd Gegenionenaustauschverfahren für peptide
EP1809663B1 (en) * 2004-11-09 2008-09-17 Ares Trading S.A. Method for purifying fsh
US20080219952A1 (en) * 2005-08-26 2008-09-11 Ares Trading S.A. Process For the Preparation of Glycosylated Interferon Beta
JP5199112B2 (ja) * 2005-12-09 2013-05-15 アレス トレーディング ソシエテ アノニム Fsh又はfsh変異体を精製するための方法
EP2203465A1 (en) * 2007-10-22 2010-07-07 Merck Serono S.A. Method for purifying an fc-containing protein
CA2702448A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying fc-fusion proteins
CN101928342B (zh) * 2009-06-18 2013-05-08 上海天伟生物制药有限公司 一种高纯度绝经期促性腺素及其制备方法和用途
WO2015168622A1 (en) * 2014-05-01 2015-11-05 Virginia Tech Intellectual Properties, Inc. Keratin nanomaterials and methods of production
CN104569441B (zh) * 2015-01-19 2016-02-03 成都大熊猫繁育研究基地 大熊猫尿液促黄体素的酶联检测方法及其应用
CA3140267A1 (en) 2019-05-16 2020-11-19 Ceva Sante Animale Compositions and methods for increasing reproduction performance in non-human mammals using recombinant luteinizing hormone

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002757A1 (en) * 1988-09-02 1990-03-22 Integrated Genetics, Inc. Heteropolymeric protein
DE122010000006I2 (de) * 1989-02-21 2012-06-21 Univ Washington Modifizierte formen von fortpflanzungshormonen.
US5087615A (en) * 1989-03-17 1992-02-11 Applied Research Systems Ars Holding N.V. Novel method of ovulation induction in humans
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
IT1287138B1 (it) * 1996-11-07 1998-08-04 Ibsa Inst Biochimique Sa Procedimento per la separazione e purificazione di fsh e lh
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
AU747179B2 (en) * 1997-06-25 2002-05-09 Merck Serono Sa Disulfide cross-linked glycoprotein hormone analogs, their preparation and use
HRP20020651B1 (en) * 2000-02-22 2011-01-31 Laboratoires Serono Sa Purified lh

Similar Documents

Publication Publication Date Title
MXPA03010402A (es) Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina.
EP0911033A3 (en) Methods and compositions for the treatment of diseases with interferon while reducing side effects
HU9300541D0 (en) Ligand to receptor c-kit qnd method for its utilization
DK281184A (da) Galeniske praeparatformer for orale antidiabetica og fremgangsmaade til deres fremstilling
MXPA02002895A (es) Tratamiento topico de infecciones por estreptococcus.
WO1994006449A3 (en) Morphogen-induced liver regeneration
IL161177A0 (en) Pharmaceutical preparation useful for treating tumors and lesions of the skin and the mucous membranes and methods and kits using same
CA2399100A1 (en) Purified lh
WO2005027936A3 (en) Pharmaceutical compositions and therapeutical treatment with oligo-beta-(1, 3)-glucans
JP2002530353A5 (cg-RX-API-DMAC7.html)
JP2003514025A5 (cg-RX-API-DMAC7.html)
WO2002065989A3 (en) Aminoglycoside treatment for lysosomal storage diseases
WO1996030042A3 (en) Methods of treating inflammation and compositions therefor
Capizzi Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside
WO2004043373A3 (en) Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
EP0795332A3 (en) Medical use of gamma-interferon in interstitial lung diseases
WO1990004977A3 (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
EE200200695A (et) (-)-5-(3-klorofenüül)-alfa-(4-klorofenüül)-alfa-(1-metüül-1H-imidasool-5-üül)tetrasolo -[1,5-a]kinasoliin-7-metaanamiin, selle valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetodselle valmistamiseks
RU98112608A (ru) Иммуногенная композиция [на основе] tlp
MXPA01012936A (es) Composicion farmaceutica que contiene sibutramina y orlistat.
WO2001083722A3 (en) Enzymes useful for treating and methods for treating mps-vi and cells lines for producing such enzymes recombinantly
JP2001288110A5 (cg-RX-API-DMAC7.html)
CA2530611A1 (en) Biologically active peptide comprising tyrosyl-seryl-valine (ysv)
JP2002529515A5 (cg-RX-API-DMAC7.html)
MXPA05012826A (es) Compuestos utiles en la terapia de la enfermedad de alzheimer y formulaciones que los contienen.